title: Effects of β2-adrenergic stimulation on exercise capacity in normal subjects.
abstract: β2-Adrenergic receptor agonists are believed to present with ergogenic properties. However, how combined respiratory, cardiovascular and muscular effects of these drugs might affect exercise capacity remain incompletely understood. The effects of salbutamol were investigated in 23 healthy subjects. The study was randomised, placebo-controlled in double-blind and followed a cross-over design. Salbutamol was given at the dose of 10 μg/min in 11 subjects and 20 μg/min iv in the other 12 subjects. Measurements included muscle sympathetic nerve activity (MSNA), ventilatory responses to hyperoxic hypercapnia (7% CO(2) in O(2,) central chemoreflex), isocapnic hypoxia (10% O(2) in N(2), peripheral chemoreflex) and isometric muscle contraction followed by a local circulatory arrest (metaboreflex), cardiopulmonary exercise test (CPET) variables and isokinetic muscle strength. Salbutamol 10 μg/min increased heart rate and blood pressure, while MSNA burst frequency remained unchanged. Peripheral chemosensitivity increased, as evidenced by an increased ventilatory response to hypoxia, but ventilatory responses to hypercapnia or muscle ischaemia remained unchanged. The effects of salbutamol 20 μg/min were similar. Both doses of salbutamol did not affect CPET. Only the higher dose of salbutamol decreased the anaerobic threshold, but this was not associated with a change in VO(2) max. Salbutamol increased the slopes of ventilation as a function of VO(2) (P < 0.05) and VCO(2) (P < 0.001) during CPET. Maximal isokinetic muscle strength was not affected by salbutamol. In conclusion, the acute administration of either low or high dose salbutamol does not affect exercise capacity in normal subjects, in spite of an earlier anaerobic threshold and increased chemosensitivity.
authors.affiliation: Department of Cardiology, Erasme University Hospital, Brussels, Belgium.
authors.forename: S P
authors.initials: SP
authors.lastname: Beloka
authors.forename: C
authors.initials: C
authors.lastname: Janssen
authors.forename: E
authors.initials: E
authors.lastname: Woff
authors.forename: E
authors.initials: E
authors.lastname: Brassine
authors.forename: G
authors.initials: G
authors.lastname: Deboeck
authors.forename: J
authors.initials: J
authors.lastname: Randria
authors.forename: V
authors.initials: V
authors.lastname: Philippart de Foy
authors.forename: P
authors.initials: P
authors.lastname: van de Borne
authors.forename: R
authors.initials: R
authors.lastname: Naeije
mesh_terms: D058666:Adrenergic beta-2 Receptor Agonists / Q000494:pharmacology*; D000328:Adult; D000420:Albuterol / Q000494:pharmacology*; D054874:Athletic Performance / Q000502:physiology; D018592:Cross-Over Studies; D004311:Double-Blind Method; D015444:Exercise / Q000502:physiology; D005080:Exercise Test; D017079:Exercise Tolerance / Q000187:drug effects* / Q000502:physiology; D006262:Health; D006801:Humans; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects / Q000294:innervation; D010919:Placebos; D012123:Pulmonary Ventilation / Q000187:drug effects / Q000502:physiology; D018343:Receptors, Adrenergic, beta-2 / Q000378:metabolism; D013564:Sympathetic Nervous System / Q000187:drug effects / Q000502:physiology; D055815:Young Adult
chemical_list: D058666:Adrenergic beta-2 Receptor Agonists; D010919:Placebos; D018343:Receptors, Adrenergic, beta-2; D000420:Albuterol